Sugi Predict

Sugi Predict / Compounds / SCHEMBL4871750

SCHEMBL4871750

SCHEMBL4871750

O=C(O)c1cc(CC2CCC2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.46
▸ KDM5B Q9UGL1 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ ASPH Q12797 3/20 0.46
▸ KDM8 Q8N371 3/20 0.46
▸ KDM4C Q9H3R0 3/20 0.46
▸ KDM5A P29375 2/20 0.46
▸ KDM6B O15054 1/20 0.46
▸ TET3 O43151 1/20 0.46
▸ KDM4A O75164 1/20 0.46
▸ BBOX1 O75936 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KDM5C P41229 1/20 0.46
▸ KDM4D Q6B0I6 1/20 0.46
▸ TET2 Q6N021 1/20 0.46
▸ ALKBH5 Q6P6C2 1/20 0.46
▸ KDM7A Q6ZMT4 1/20 0.46
▸ TET1 Q8NFU7 1/20 0.46
▸ EGLN2 Q96KS0 1/20 0.46
▸ FTO Q9C0B1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998746 0.94 KDM4E (0.49) KDM4EKDM5BALDH1A1ASPHKDM8
SCHEMBL4870118 0.86 LNPEP (0.46) KDM4EKDM5BALDH1A1ASPHKDM8
SCHEMBL28097363 0.84 NPC1 (0.45) KDM4EKDM5BASPHKDM8KDM5A
SCHEMBL27661994 0.79 KDM4E (0.47) KDM4EKDM5BALDH1A1ASPHKDM8
SCHEMBL27975139 0.79 OPRM1 (0.44) SMYD3CYP4F2CYP4A11
SCHEMBL25522099 0.77 KDM5B (0.36) KDM5BKDM5ASMN1; SMN2SMYD3
SCHEMBL24589247 0.76 KDM5B (0.35) KDM5BKDM5ASMN1; SMN2SMYD3
SCHEMBL25662543 0.75 SMYD3 (0.37) KDM4EKDM5BALDH1A1KDM5ASMN1; SMN2
SCHEMBL743017 0.74 KDM4E (0.57) KDM4EKDM5BALDH1A1ASPHKDM8
SCHEMBL30112054 0.74 KDM4E (0.57) KDM4EKDM5BALDH1A1ASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1823083-B Lincomycin derivatives with antimicrobial activity VICURON PHARM INC 2010-05-26 — — CN disclosed
US-7361743-B2 Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides PFIZER INC (US) 2008-04-22 — — US disclosed
US-7256177-B2 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS, INC. (US) 2007-08-14 — — US disclosed
EP-1814893-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2007-08-08 — — EP disclosed
US-7199105-B2 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS, INC. (US) 2007-04-03 — — US disclosed
US-7199106-B2 Lincomycin derivatives possessing antimicrobial activity VICURON PHARMACEUTICALS, INC. (US) 2007-04-03 — — US disclosed
CN-1823083-A Novel lincomycin derivatives with antimicrobial activity VICURON PHARM INC (US) 2006-08-23 — — CN disclosed
US-20060148722-A1 Novel lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-07-06 — — US disclosed
WO-2006055070-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2006-05-26 — — WO disclosed
EP-1654268-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2006-05-10 — — EP disclosed
EP-1644393-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2006-04-12 — — EP disclosed
US-20050215488-A1 Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides VICURON PHARMACEUTICALS INC. 2005-09-29 — — US disclosed
US-20050043248-A1 Novel lincomycin derivatives possessing antimicrobial activity VICURON PHARMACEUTICALS INC. 2005-02-24 — — US disclosed
WO-2005012320-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2005-02-10 — — WO disclosed
WO-2005007665-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2005-01-27 — — WO disclosed
US-20040230046-A1 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. 2004-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040230046-A1 Lincomycin derivatives possessing antibacterial activity NRDC, NISCH, CLSPN KDM4E 3921/4885KDM5B 2964/4885ALDH1A1 2737/4885
US-20060148722-A1 Novel lincomycin derivatives possessing antibacterial activity LCLAT1, LAS1L, NRDC KDM4E 3409/4885KDM5B 2343/4885ALDH1A1 2927/4885
US-20050215488-A1 Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides PAM, MLYCD, PPT1 KDM4E 970/4885KDM5B 873/4885ALDH1A1 2254/4885
US-20050043248-A1 Novel lincomycin derivatives possessing antimicrobial activity LCLAT1, NRDC, LAS1L KDM4E 3516/4885KDM5B 2561/4885ALDH1A1 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.